

REMARKS

At the Examiner interview on September 21, 2010, it was suggested that incorporating the recitation of the release profile into claim 33 could receive favorable consideration. The present amendment incorporates the recitation of the release profile into claim 33. Claims 1, 6, 7, 9, 10, 12-32, 35, and 36 have been canceled without prejudice. Claim 33 has been amended and claims 37-42 have been added. No new matter has been added. Claims 33, 34, and 37-42 are pending.

Applicants submit that the amended and newly presented claims are supported by the specification as filed. New claim 37 includes recitations from canceled claim 6. New claim 38 includes recitations from canceled claim 27. New claim 39 includes recitations from canceled claim 28. New claim 40 includes recitations from canceled claim 10. New claim 41 includes recitations from canceled claim 21. New claim 42 includes recitations from canceled claim 26.

The primary reference cited in the obviousness rejections discloses composition in the form of a tablet. This reference neither discloses nor suggests a composition "suitable for oral administration and in the form of coated, flowable granules" with "the coated, flowable granules being in a sachet, capsule or blister package". Further, this reference neither discloses nor suggests a composition having the release profile recited in amended claim 33. The release profile is discussed in detail in the Amendment that was submitted on June 2, 2010.

Applicants respectfully submit that the amended and newly presented claims are in condition for allowance, and notification to that effect is earnestly solicited.

Summary

In view of the above amendments and remarks, Applicant respectfully requests a Notice of Allowance. If the Examiner believes a telephone conference would advance the prosecution of this application, the Examiner is invited to telephone the undersigned at the below-listed telephone number.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate.


U.S. Patent Application Serial No. 10/553,629
Supplemental Amendment

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: 22 Oct '10


Mark T. Skoog
Reg. No. 40,178

MTS:kf

